DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zenapax (Daclizumab) - Published Studies

 
 



Zenapax Related Published Studies

Well-designed clinical trials related to Zenapax (Daclizumab)

Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. [2014]

Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis. [2014]

Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. [2010.11]

Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. [2010.06.27]

Daclizumab for relapsing remitting multiple sclerosis. [2010.06.16]

Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study. [2010.04.27]

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. [2010.04]

Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. [2010.04]

Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. [2010.01]

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. [2010]

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. [2009.12]

A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. [2009.11]

Impact of daclizumab, low-dose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. [2009.09.22]

Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. [2009.06]

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. [2008.12.27]

Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. [2008.11.15]

A randomized, controlled trial of daclizumab vs anti-thymocyte globulin induction for lung transplantation. [2007.05]

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. [2007.03]

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet's disease. [2007.03]

Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. [2006.07.15]

Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study. [2006.05]

A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. [2006.04]

Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. [2005.09]

Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. [2005.08.27]

Daclizumab to prevent rejection after cardiac transplantation. [2005.06.30]

Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants. [2005.06]

Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial. [2005.05]

Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. [2005.04.15]

Daclizumab is associated with decreased rejection and no increased mortality in cardiac transplant patients receiving MMF, cyclosporine, and corticosteroids. [2005.03]

Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study. [2005.01]

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. [2004.09.01]

One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. [2004.05]

Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors. [2004]

Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. [2003.12]

Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab. [2003.08]

Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. [2003.04.27]

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. [2003.01]

A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis. [2002.02]

Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. [2002]

Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. [2001.12]

Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. [2001.11.27]

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. [2001.09.15]

Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. [2000]

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. [1999.07.27]

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. [1999.01.15]

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. [1998.01.15]

Well-designed clinical trials possibly related to Zenapax (Daclizumab)

Randomized trial of immunosuppressive regimens in renal transplantation. [2011.09]

Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. [2011.06.15]

A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. [2010.11]

Preliminary results of a prospective randomized study of cyclosporine versus tacrolimus in the development of cardiac allograft vasculopathy at 1 year after heart transplantation. [2010.10]

Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. [2010.06]

A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. [2010.04]

Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. [2009.12]

Clinical rejection and persistent immune regulation in kidney transplant patients. [2009.07]

Health-related quality of life of patients receiving low-toxicity immunosuppressive regimens: a substudy of the Symphony Study. [2009.04.27]

Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study. [2009.01]

Monoclonal antibodies in the therapy of multiple sclerosis: an overview. [2008.12]

Reduced exposure to calcineurin inhibitors in renal transplantation. [2007.12.20]

Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. [2007.10.15]

Exploratory calcineurin inhibitor-free regimens in living-related kidney transplant recipients. [2007.04]

High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. [2006.11.15]

WOFIE stimulates regulatory T cells: a 2-year follow-up of renal transplant recipients. [2006.06.15]

Choice of antibody immunotherapy influences cytomegalovirus viremia in simultaneous pancreas-kidney transplant recipients. [2006.04]

Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function. [2006]

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. [2005.08.27]

Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. [2005.08]

A multicenter analysis of the significance of HLA matching on outcomes after kidney-pancreas transplantation. [2005.03]

Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study. [2005.03]

Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients. [2005.03]

The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation. [2005.03]

No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study. [2004.07.15]

Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study. [2004.05]

Long-term outcome of sirolimus rescue in kidney-pancreas transplantation. [2004.05]

A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. [2004.01.27]

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. [2003.11]

[Cytokines and growth factors serum level and renal allograft function (preliminary report)] [2003.10]

The role of the protocol biopsies in renal allograft recipients. [2003.09]

Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. [2003.09]

Anti-CD25 monoclonal antibody therapy affects the death signals of graft-infiltrating cells after clinical heart transplantation. [2003.05.27]

WOFIE synergizes with calcineurin-inhibitor treatment and early steroid withdrawal in kidney transplantation. [2003.04.27]

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. [2002.07]

Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. [2000.03.02]

The use of antibodies against the IL-2 receptor in transplantation. [1998.10]

Other research related to Zenapax (Daclizumab)

Combination of a low dose of daclizumab and standard regimen for prevention of rejection in men and women receiving a kidney transplant. [2013]

WITHDRAWN: Coenzyme Q10 for Parkinson's disease. [2012]

Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. [2011.12]

Intrathecal effects of daclizumab treatment of multiple sclerosis. [2011.11.22]

Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid. [2011.07]

A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation. [2011.07]

Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation. [2011.03]

Repeated daclizumab administration to delay the introduction of calcineurin inhibitors in heart transplant patients with postoperative renal dysfunction. [2011.03]

Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. [2011.03]

Systemic monoclonal antibody therapy (daclizumab) in the treatment of cicatrizing conjunctivitis in stevens-johnson syndrome, refractory to conventional therapy. [2010.12]

Structural basis of immunosuppression by the therapeutic antibody daclizumab. [2010.12]

Daclizumab: a potential asthma therapy? [2010.11]

Daclizumab induction therapy in liver transplant recipients with renal insufficiency. [2010.09]

A prospective randomized study comparing cyclosporine versus tacrolimus combined with daclizumab, mycophenolate mofetil, and steroids in heart transplantation. [2010.07.28]

Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation. [2010.07]

Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab. [2010.03]

Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. [2010.01]

Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. [2010]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017